Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GENE THERAPY, OPEN-LABEL, DOSE-ESCALATION STUDY OF SPK-9001 [ADENO-ASSOCIATED VIRAL VECTOR WITH HUMAN FACTOR IX GENE] IN SUBJECTS WITH HEMOPHILIA B

Trial Profile

GENE THERAPY, OPEN-LABEL, DOSE-ESCALATION STUDY OF SPK-9001 [ADENO-ASSOCIATED VIRAL VECTOR WITH HUMAN FACTOR IX GENE] IN SUBJECTS WITH HEMOPHILIA B

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fidanacogene-elaparvovec (Primary)
  • Indications Haemophilia B
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer; Spark Therapeutics
  • Most Recent Events

    • 12 Dec 2023 Results reporting descriptive data on impact on HRQoL for participants in the fidanacogene elaparvovec phase 1/2a study (NCT02484092) and its LTU study (NCT03307980) presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 14 Dec 2021 Results assessing Follow-up of More Than 5 Years presented at the 63rd American Society of Hematology Annual Meeting and Exposition
    • 07 Jan 2020 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top